Literature DB >> 26410742

Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis.

Rick Dersch1, Antonia A Sarnes2, Monika Maul2, Tilman Hottenrott2, Annette Baumgartner2, Sebastian Rauer2, Oliver Stich2.   

Abstract

The prognosis and impact of residual symptoms on quality of life in patients with Lyme neuroborreliosis (LNB) is subject to debate. The aim of this study was to assess quality of life, fatigue, depression, cognitive impairment and verbal learning in patients with definite LNB and healthy controls in a case-control study. We retrospectively identified all patients diagnosed with definite LNB between 2003 and 2014 in our tertiary care center. Healthy controls were recruited from the same area. Patients and healthy controls were assessed for quality of life [Short Form (36) with subscores for physical and mental components (PCS, MCS)], fatigue (fatigue severity scale), depression (Beck depression inventory), verbal memory and learning and cognitive impairment (mini-mental state examination). 53 patients with definite LNB could be identified, of which 30 partook in the follow-up assessment. Estimates for quality of life, fatigue, depression, verbal memory and cognitive impairment did not differ statistically significantly between 30 patients with LNB and 35 healthy controls. Patients with residual symptoms had lower scores for quality of life (PCS) compared to patients without residual symptoms. Our results do not support the hypothesis that a considerable proportion of patients with antibiotically treated LNB develop a 'post Lyme syndrome' consisting of debilitating fatigue or cognitive impairment or have severe limitations of quality of life. However, some patients experience residual symptoms of LNB.

Entities:  

Keywords:  Case–control study; Cognitive impairment; Depression; Fatigue; Follow-up; Lyme neuroborreliosis; Quality of life; Verbal memory

Mesh:

Substances:

Year:  2015        PMID: 26410742     DOI: 10.1007/s00415-015-7891-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

Review 1.  EQ-5D: a measure of health status from the EuroQol Group.

Authors:  R Rabin; F de Charro
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

2.  Death due to community-associated Clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected lyme disease.

Authors:  Stacy M Holzbauer; Melissa M Kemperman; Ruth Lynfield
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Evidence-based guidelines for the management of Lyme disease.

Authors:  Daniel Cameron; Andrea Gaito; Nick Harris; Gregory Bach; Sabra Bellovin; Kenneth Bock; Steven Bock; Joseph Burrascano; Constance Dickey; Richard Horowitz; Steven Phillips; Laurence Meer-Scherrer; Bernard Raxlen; Virginia Sherr; Harold Smith; Pat Smith; Raphael Stricker
Journal:  Expert Rev Anti Infect Ther       Date:  2004       Impact factor: 5.091

4.  Bannwarth's syndrome and the enlarged neurological spectrum of arthropod-borne borreliosis.

Authors:  H W Pfister; K M Einhäupl; B Wilske; V Preac-Mursic
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

5.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

6.  Antiscience and ethical concerns associated with advocacy of Lyme disease.

Authors:  Paul G Auwaerter; Johan S Bakken; Raymond J Dattwyler; J Stephen Dumler; John J Halperin; Edward McSweegan; Robert B Nadelman; Susan O'Connell; Eugene D Shapiro; Sunil K Sood; Allen C Steere; Arthur Weinstein; Gary P Wormser
Journal:  Lancet Infect Dis       Date:  2011-09       Impact factor: 25.071

7.  Incidence of Lyme borreliosis in the Würzburg region of Germany.

Authors:  H I Huppertz; M Böhme; S M Standaert; H Karch; S A Plotkin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

8.  European neuroborreliosis: neuropsychological findings 30 months post-treatment.

Authors:  R Eikeland; U Ljøstad; A Mygland; K Herlofson; G C Løhaugen
Journal:  Eur J Neurol       Date:  2011-10-15       Impact factor: 6.089

9.  Lyme encephalopathy: long-term neuropsychological deficits years after acute neuroborreliosis.

Authors:  T Benke; T Gasse; M Hittmair-Delazer; E Schmutzhard
Journal:  Acta Neurol Scand       Date:  1995-05       Impact factor: 3.209

10.  Subjective symptoms after treatment of early Lyme disease.

Authors:  Dasa Cerar; Tjasa Cerar; Eva Ruzić-Sabljić; Gary P Wormser; Franc Strle
Journal:  Am J Med       Date:  2010-01       Impact factor: 4.965

View more
  12 in total

Review 1.  [Neuroborreliosis - Diagnostics, treatment and course].

Authors:  R Dersch; S Rauer
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

2.  Long-Term Sequelae and Health-Related Quality of Life Associated With Lyme Disease: A Systematic Review.

Authors:  Stephen Mac; Simran Bahia; Frances Simbulan; Eleanor M Pullenayegum; Gerald A Evans; Samir N Patel; Beate Sander
Journal:  Clin Infect Dis       Date:  2020-07-11       Impact factor: 9.079

Review 3.  Challenges in the Diagnosis and Treatment of Lyme Disease.

Authors:  Robert T Schoen
Journal:  Curr Rheumatol Rep       Date:  2020-01-07       Impact factor: 4.592

4.  Neuroborreliosis.

Authors:  John J Halperin
Journal:  J Neurol       Date:  2016-11-24       Impact factor: 4.849

5.  Cognitive function in patients with neuroborreliosis: A prospective cohort study from the acute phase to 12 months post treatment.

Authors:  Silje Andreassen; Anne Marit Solheim; Unn Ljøstad; Åse Mygland; Åslaug Rudjord Lorentzen; Harald Reiso; Mona Kristiansen Beyer; Hanne Flinstad Harbo; Gro Christine Christensen Løhaugen; Randi Eikeland
Journal:  Brain Behav       Date:  2022-05-20       Impact factor: 3.405

6.  Characterization of Brain Dysfunction Induced by Bacterial Lipopeptides That Alter Neuronal Activity and Network in Rodent Brains.

Authors:  Kwang-Min Kim; Alsu I Zamaleeva; Youn Woo Lee; M Rafiuddin Ahmed; Eunkyung Kim; Hye-Ryeon Lee; Venkata Raveendra Pothineni; Juan Tao; Siyeon Rhee; Mithya Jayakumar; Mohammed Inayathullah; Senthilkumar Sivanesan; Kristy Red-Horse; Theo D Palmer; Jon Park; Daniel V Madison; Ho-Young Lee; Jayakumar Rajadas
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

7.  Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization.

Authors:  Philipp Schwenkenbecher; Refik Pul; Ulrich Wurster; Josef Conzen; Kaweh Pars; Hans Hartmann; Kurt-Wolfram Sühs; Ludwig Sedlacek; Martin Stangel; Corinna Trebst; Thomas Skripuletz
Journal:  BMC Infect Dis       Date:  2017-01-21       Impact factor: 3.090

8.  It's Never Too Early or Too Late-End the Epidemic of Alzheimer's by Preventing or Reversing Causation From Pre-birth to Death.

Authors:  Clement L Trempe; Thomas J Lewis
Journal:  Front Aging Neurosci       Date:  2018-07-12       Impact factor: 5.750

9.  Long term survival, health, social functioning, and education in patients with European Lyme neuroborreliosis: nationwide population based cohort study.

Authors:  Niels Obel; Ram B Dessau; Karen A Krogfelt; Jacob Bodilsen; Nanna S Andersen; Jens K Møller; Casper Roed; Lars H Omland; Claus B Christiansen; Svend Ellermann-Eriksen; Jette M Bangsborg; Klaus Hansen; Thomas L Benfield; Kenneth J Rothman; Henrik T Sørensen; Christian Ø Andersen; Anne-Mette Lebech
Journal:  BMJ       Date:  2018-05-30

10.  Psychosocial predictors of quality of life among South Africa adolescents receiving antiretroviral therapy.

Authors:  A Kagee; B Coetzee; S Du Toit; M E Loades
Journal:  Qual Life Res       Date:  2018-09-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.